Webdisclosure.com

NEWRON PHARMACEUTICALS S.P.A.

15/05/2023 07:00

EQS-News: Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

03/05/2023 07:00

EQS-News: Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

02/05/2023 07:00

EQS-News: Newron announces Senior Management Team changes

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

18/04/2023 12:15

EQS-News: Newron announces AGM 2023 results

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

28/03/2023 12:30

EQS-News: Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

20/03/2023 07:00

EQS-News: Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

17/03/2023 07:00

EQS-News: Newron to present at the 31st European Congress of Psychiatry

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

14/03/2023 07:00

EQS-News: Newron announces 2022 financial results and provides outlook for 2023

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

16/02/2023 07:00

EQS-News: Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

03/01/2023 07:00

EQS-News: Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

1
2
3
4
5
6
7
8
9
10